Samer Shihabi, MD
Medical Oncology · Sacramento, CANPI 1730110768
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $3,538 of the $4,310 with a category attached, or 82.1%. AstraZeneca accounts for 84.4% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2020 at $2,322 and has fallen 97.2% since, to $65 in 2025. That places this record below the midpoint for medical oncology clinicians in CA, where the typical reported total is $4,042.
Across 20 payments — averaging $215.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$4K
- Novocure GmbH$200
- US Oncology Corporate, Inc.$112
- Comsort, Inc$100
- Mckesson Specialty Care Distribution, LLC$91
- E.r. Squibb & Sons, L.L.C.$58
- plus $112 from 5 others
Across 11 payments — averaging $3614.25 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novocure Inc.$30K
- Pfizer$10K
What the payments were for
- Consulting fees$3,53882%
- Speaking & faculty fees$4009%
- Food & beverage$2786%
- Education$952%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 3 | $3,638 |
| Novocure GmbH | 1 | $200 |
| US Oncology Corporate, Inc. | 4 | $112 |
| Comsort, Inc | 1 | $100 |
| Mckesson Specialty Care Distribution, LLC | 2 | $91 |
| E.r. Squibb & Sons, L.L.C. | 3 | $58 |
| Pfizer | 2 | $45 |
| Hologic Sales And Service, LLC | 1 | $22 |
| Eisai Inc. | 1 | $22 |
| Gilead | 1 | $12 |
| Johnson & Johnson | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,310 in reported general payments places this provider in the 50th percentile of 379 medical oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 40 | $745,031 |
| VenclextaVenetoclax | 34 | $474,721 |
| LenvimaLenvatinib Mesylate | 18 | $446,510 |
| TagrissoOsimertinib Mesylate | 25 | $416,932 |
| IbrancePalbociclib | 26 | $410,573 |
| CalquenceAcalabrutinib Maleate | 27 | $375,283 |
| OrserduElacestrant Hcl | 12 | $350,900 |
| SprycelDasatinib | 24 | $311,495 |
| XtandiEnzalutamide | 22 | $305,772 |
| LynparzaOlaparib | 23 | $304,132 |
| KisqaliRibociclib Succinate | 17 | $260,971 |
| Lenalidomide | 25 | $243,704 |
| BraftoviEncorafenib | 14 | $219,187 |
| DopteletAvatrombopag Maleate | 15 | $119,751 |
| Everolimus | 11 | $115,907 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaTagrisso, Calquence, Lynparza | $3,638 | $1,096,34775 claims |
| Eisai Inc.Lenvima | $22 | $446,51018 claims |
| PfizerIbrance, Eliquis | $45 | $425,45748 claims |
| E.r. Squibb & Sons, L.L.C.Sprycel | $58 | $311,49524 claims |
| Johnson & JohnsonXarelto | $11 | $22,75925 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 379 medical oncology providers in California.
Other medical oncology in Sacramento
- Stephen SherwinSan Francisco$6.9M
- Noam DrazinBeverly Hills$1.4M
- Farshid DayyaniOrange$1.2M
- April TeitelbaumSan Diego$1.1M
- Przemyslaw TwardowskiSanta Monica$995K
- Ann LowePalo Alto$923K
- Marin XavierSan Diego$919K
- Munveer Bhangoola Jolla$804K
- Stephen LiuLos Angeles$750K
- Jacek PinskiLos Angeles$672K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.